131 () posted 1 year ago by wrmevlp 1 year ago by wrmevlp +131 / -0 11 comments share 11 comments share save hide report block hide replies
Very expensive manufactured mono-clonal antibodies is their cash model, With more side effects than horse paste it opens other revenue pathways.